๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A regimen of surgical adjuvant immunotherapy for cancer with interleukin 2 and lymphokine-activated killer cells

โœ Scribed by Tokujiro Yano; Teruyoshi Ishida; Ichiro Yoshino; Mitsuhiro Murata; Kosei Yasumoto; Genki Kimura; Kikuo Nomoto; Keizo Sugimachi

Publisher
Springer
Year
1991
Tongue
English
Weight
670 KB
Volume
3
Category
Article
ISSN
0921-299X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Immunotherapy of cancer with lymphokines
Immunotherapy of cancer with lymphokines and lymphokine-activated killer cells
โœ John W. Yarbro ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 996 KB

Our expanding knowledge of the immune system has provided a basis of rationality for immunotherapy . Some non-specific immunotherapy has achieved the status of standard treatment: interferon in hairy cell leukemia and chronic myelogenous leukemia, BCG in bladder cancer, and levamisole in colon cance

The requirements for successful immunoth
The requirements for successful immunotherapy of intraperitoneal cancer using interleukin-2 and lymphokine-activated killer cells
โœ Reyer T. Ottow; Alexander M. M. Eggermont; E. Philip Steller; Paul H. Sugarbaker ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 907 KB

In a significant proportion of patients with gastrointestinal and ovarian malignancy the peritoneal cavity is a prominent site at which surgical treatment fails. Adjuvant treatments directed at this site should be investigated in an attempt to improve survival in patients with these cancers. In the

Adoptive immunotherapy for recurrent gli
Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2
โœ Randall E. Merchant; Angus J. Grant; Lynn H. Merchant; Harold F. Young ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 565 KB

Thirteen patients with recurrent glioblastoma were treated with adoptively transferred autologous lymphokine activated killer (LAK) cells and recombinant interleukin-2 (rIL-2). Patients' blood mononuclear cells (MNC) obtained by leukapheresis were cultured at 2.5 million MNC per ml for 3 to 5 days i

Adoptive immunotherapy with lymphokine-a
Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma
โœ Saburo Onishi; Toshiji Saibara; Masanao Fujikawa; Hiroshi Sakaeda; Yasushi Matsu ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 591 KB

Ten patients with hepatocellular carcinoma, three of whom had pulmonary metastasis, were treated with adoptive immunotherapy using autologous lymphokineactivated killer cells plus recombinant interleukin 2. Patients received 16 pg per day of recombinant interleukin 2 consecutively (for 14 to 64 days